Status:

COMPLETED

A Methodology Study in Healthy Subjects to Evaluate the Effect of AZD8309 After Nasal Administration of Lipopolysaccharide (LPS)

Lead Sponsor:

AstraZeneca

Conditions:

Healthy

Eligibility:

All Genders

18-50 years

Phase:

NA

Brief Summary

The purpose of this methodology study is to evaluate the effect of AZD8309 on cells and inflammatory biomarkers in nasal lavage and blood after nasal challenge with lipopolysaccharide (LPS)

Eligibility Criteria

Inclusion

  • Healthy men or healthy, permanently sterilized, women aged 18 to 50 years inclusive, non-smokers or ex-smokers, Body Mass Index 18 to 30 kg/m2 and minimum body weight of 50 kg
  • Blood neutrophil count above 2.2x10\^9/L

Exclusion

  • Clinical relevant disease and/or abnormality

Key Trial Info

Start Date :

March 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

October 1 2009

Estimated Enrollment :

20 Patients enrolled

Trial Details

Trial ID

NCT00860821

Start Date

March 1 2009

End Date

October 1 2009

Last Update

October 28 2009

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Research Site

Malmo, Sweden